Swiss pharma giant Roche’s RHHBY Genentech announced a significant expansion of its original investment in a new manufacturing facility in Holly Springs, NC.
Genentech will more than double the initial investment in a state-of-the-art biomanufacturing facility in Holly Springs to approximately $2 billion, fueling Roche’s intensifying focus on U.S.-based manufacturing, supply-chain resilience and next-generation therapeutic growth areas.
In May 2025, Genentech announced plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs. Thereafter, in August 2025, it broke ground on its manufacturing site in Holly Springs…